Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
A Phase II, Open-Label, Parallel Cohort Study Of Subcutaneous Amivantamab In Multiple Regimens In Patients With Advanced Or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor Mutated Non-Small Cell Lung Cancer PALOMA-2
Study Type: Treatment
Phase: II
NCTID: NCT05498428
Principal Investigator:
Chao Huang
Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer
Study Type: Treatment
Phase: III
NCTID: NCT05624996
Principal Investigator:
Krishna Reddy
A Randomized Phase III Trial INcorporating Pathologic Complete ReSponse in Participants with Early StaGe Non Small Cell Lung Cancer to Optimize ImmunotHerapy in the AdjuvanT Setting INSIGHT
Study Type: Treatment
Phase: III
NCTID: NCT06498635
Principal Investigator:
Gary Doolittle
A Randomized Phase II/III Study of Docetaxel and Ramucirumab with or without Cemiplimab REGN2810 for Participants Previously Treated with Platinum-based Chemotherapy and Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer Lung-MAP Non-Matched Sub-Study
Study Type: Treatment
Phase: II/III
NCTID: NCT06616584
Principal Investigator:
Anusha Chidharla
RASolve 301: Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 versus Docetaxel in Patients with Previously Treated Locally Advanced or Metastatic RASMUT NSCLC
Study Type: Treatment
Phase: III
NCTID: NCT06881784
Principal Investigator:
Chao Huang
A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer Lung-MAP Screening Study
Study Type: Screening
Phase: III
NCTID: NCT03851445
Principal Investigator:
Anusha Chidharla
An Open-label Multi-Cohort Phase 1b/2 Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination with a PD-1 Immune Checkpoint Inhibitor in Advanced or Metastatic Non-Squamous NSCLC with No Prior Treatment for Advanced Disease and No Actionable Genomic Alterations AndroMETa-Lung-536
Study Type: Treatment
Phase: I/II
NCTID: NCT06772623
Principal Investigator:
Chao Huang
A Randomized Phase II Study of INC280 capmatinib plus Osimertinib with or without Ramucirumab in Participants with EGFR-Mutant, METAmplified Stage IV or Recurrent Non-Small Cell Lung Cancer Lung-MAP Sub-Study
Study Type: Treatment
Phase: II
NCTID: NCT05642572
Principal Investigator:
Anusha Chidharla
CAFs Combination of Atezolizumab and pirfenidone in Second-line and Beyond NSCLC: a Phase I/II study
Study Type: Treatment
Phase: I/II
NCTID: NCT04467723
Principal Investigator:
Chao Huang
A Randomized Phase III Trial of Chemo-Immunotherapy vs Immunotherapy Alone for the Vulnerable older adult with Advanced Non-Small Cell Lung Cancer: The ACHIEVE Study
Study Type: Treatment
Phase: III
NCTID: NCT06096844
Principal Investigator:
Anusha Chidharla